204 related articles for article (PubMed ID: 36316040)
21. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G
Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626
[TBL] [Abstract][Full Text] [Related]
22. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
[TBL] [Abstract][Full Text] [Related]
23. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
[TBL] [Abstract][Full Text] [Related]
24. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
26. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Davies KD; Le AT; Theodoro MF; Skokan MC; Aisner DL; Berge EM; Terracciano LM; Cappuzzo F; Incarbone M; Roncalli M; Alloisio M; Santoro A; Camidge DR; Varella-Garcia M; Doebele RC
Clin Cancer Res; 2012 Sep; 18(17):4570-9. PubMed ID: 22919003
[TBL] [Abstract][Full Text] [Related]
27. Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency.
Inoue M; Toki H; Matsui J; Togashi Y; Dobashi A; Fukumura R; Gondo Y; Minowa O; Tanaka N; Mori S; Takeuchi K; Noda T
Carcinogenesis; 2016 May; 37(5):452-60. PubMed ID: 26964870
[TBL] [Abstract][Full Text] [Related]
28. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
[TBL] [Abstract][Full Text] [Related]
29. CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma.
Matsuura S; Shinmura K; Kamo T; Igarashi H; Maruyama K; Tajima M; Ogawa H; Tanahashi M; Niwa H; Funai K; Kohno T; Suda T; Sugimura H
Oncol Rep; 2013 Oct; 30(4):1675-80. PubMed ID: 23877438
[TBL] [Abstract][Full Text] [Related]
30. [Infant-type hemispheric glioma with EEF1G-ROS1 fusion: report of a case].
Gao M; Wang LM; Piao YS; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):408-410. PubMed ID: 36973207
[TBL] [Abstract][Full Text] [Related]
31. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
[TBL] [Abstract][Full Text] [Related]
32. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
[TBL] [Abstract][Full Text] [Related]
33. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
34. ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance.
Prall OWJ; Browning J; Nastevski V; Caporarello S; Bates B; Hewitt CA; Arenas A; Lamb G; Howlett K; Arnolda R; Adeloju R; Stuart S; Xu H; Fellowes A; Fox SB
Pathology; 2022 Apr; 54(3):279-285. PubMed ID: 34635319
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
[TBL] [Abstract][Full Text] [Related]
36. ROS1 Rearrangement in Thyroid Cancer.
Ritterhouse LL; Wirth LJ; Randolph GW; Sadow PM; Ross DS; Liddy W; Lennerz JK
Thyroid; 2016 Jun; 26(6):794-7. PubMed ID: 27089969
[TBL] [Abstract][Full Text] [Related]
37. Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor.
Kiehna EN; Arnush MR; Tamrazi B; Cotter JA; Hawes D; Robison NJ; Fong CY; Estrine DB; Han JH; Biegel JA
J Neurosurg Pediatr; 2017 Jul; 20(1):51-55. PubMed ID: 28387643
[TBL] [Abstract][Full Text] [Related]
38. High Prevalence of Concomitant Oncogene Mutations in Prospectively Identified Patients with ROS1-Positive Metastatic Lung Cancer.
Wiesweg M; Eberhardt WEE; Reis H; Ting S; Savvidou N; Skiba C; Herold T; Christoph DC; Meiler J; Worm K; Kasper S; Theegarten D; Hense J; Hager T; Darwiche K; Oezkan F; Aigner C; Welter S; Kühl H; Stuschke M; Schmid KW; Schuler M
J Thorac Oncol; 2017 Jan; 12(1):54-64. PubMed ID: 27575422
[TBL] [Abstract][Full Text] [Related]
39. GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types.
Sievers P; Stichel D; Sill M; Schrimpf D; Sturm D; Selt F; Ecker J; Kazdal D; Miele E; Kranendonk MEG; Tops BBJ; Kohlhof-Meinecke P; Beschorner R; Kramm CM; Hasselblatt M; Reifenberger G; Capper D; Wesseling P; Stenzinger A; Milde T; Korshunov A; Witt O; Pfister SM; Wick W; von Deimling A; Jones DTW; Sahm F
Acta Neuropathol; 2021 Dec; 142(6):1065-1069. PubMed ID: 34536122
[No Abstract] [Full Text] [Related]
40. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]